Centers for Disease Control and Prevention
National Center for Immunization and Respiratory Diseases

Adult Respiratory Syncytial Virus (RSV) Session

Camille Kotton, MD

Chair, Adult RSV Work Group

Advisory Committee on Immunization Practices (ACIP)

June 26, 2024

Adult RSV Work Group Membership

ACIP Voting Members
Camille Kotton (Chair)
Keipp Talbot
Sarah Long
Albert Shaw

Ex Officio Members
Rachel Zhang (FDA)
Nicholas Geagan (FDA)
Nadine Peart Akindele (FDA)
Sonnie Kim (NIH/NIAID)
Michelle Juaneza (HRSA)
Uzo Chukwuma (IHS)

CDC Co-Leads
Michael Melgar
Amadea Britton

Liaisons
Kenneth Schmader (AGS)
Vidya Sundareshan (ACP)
Gretchen LaSalle (AAFP)
April Killikelly (NACI, PHAC)
Winnie Siu (NACI, PHAC)
Katherine Williams (APTR)
Ruth Lynfield (NFID)
Bindy Crouch (AIM)
Steven Pergam (IDSA)
Elizabeth Skoy (APhA)

Consultants
Robert Atmar (Baylor College of Medicine)
Doug Campos-Outcalt (University of Arizona)
Helen Chu (University of Washington)
Peter Donofrio (Vanderbilt University)
Marie Griffin (Vanderbilt University)
Rebecca Morgan (Case Western Reserve University)
Cynthia Lucero-Obusan (Veterans Health Administration)
Tracy Ruckwardt (NIH/NIAID)
Jonathan Temte (University of Wisconsin)

Transition in Work Group Chair

- Dr. Albert Shaw will be the incoming work group chair for the adult RSV work group starting in July 2024.

CDC Contributors

Coronavirus and Other Respiratory Viruses Division

Melissa Coughlin
Fatima Dawood
Katherine Fleming-Dutra
Kristen Folsom
Jarrett Gartin
Monica Godfrey
Aron Hall
Fiona Havers
Michele Hlavsa
Jefferson Jones
Ruth Link-Gelles
Agustin Lopez
Josephine Mak
Meredith McMorrow
Noelle-Angelique Molinari
Danielle Moulia
Ismael Ortega-Sanchez
Lakshmi Panagiotakopoulos
Pragna Patel
Monica Patton
Amanda Payne
Derrell Powers
Mila Prill
Lauren Roper
Diya Surie
Natalie Thornburg
Raigan Wheeler
Megan Wallace
Trang Wisard

Immunization Safety Office

Anne Hause
Pedro Moro
Christine Olson
David Shay
Karen Broder
John Su
Eric Weintraub
Michael McNeil
Julianne Gee

Immunization Services Division

Carla Black
Kayla Calhoun
Jennifer Kriss
James Singleton
Nicole Dowling
Andrew Leidner
Jamison Pike
James Singleton
Patricia Wodi

Influenza Division

Jill Ferdinands
Lisa Grohskopf

NCIRD Office of the Director

Hannah Rosenblum
Melinda Wharton
Jessica MacNeil

CDC and ACIP currently recommend that adults aged 60 years and older may receive a single dose of RSV vaccination, using shared clinical decision-making.

- ACIP voted on this recommendation at the June 2023 meeting
- Recommendation is not product-specific; administer whichever vaccine is available

https://www.cdc.gov/mmwr/volumes/72/wr/mm7229a4.htm

Recap of Adult RSV session, February 2024

- Moderna presented safety and efficacy data from the first 9 months of follow up in their phase 3 trial in adults aged ≥60 years
- CDC presented risk-stratified rates of RSV-associated hospitalization in U.S. adults aged 50 years and older
- CDC gave an update on uptake and implementation of RSV vaccine in U.S. adults aged 60 years and older during the first season following the recommendation
- CDC and FDA presented on post-marketing safety of the protein subunit RSV vaccines (GSK's AREXVY and Pfizer's ABRYSVO) in adults aged 60 years and older
- CDC presented an analysis comparing the estimated magnitude of public health benefit and potential risk of Guillain-Barre syndrome (GBS) associated with protein subunit RSV vaccination in adults aged 60 years and older
- For adults aged 60 years and older who remain unvaccinated, ACIP agreed with encouraging timing of RSV vaccination in the late summer and early fall to optimize public health benefits

Recent work group discussion

- Moderna mRESVIA for use in adults aged 60 years and older (received FDA approval May 31, 2024)
- GSK AREXVY for use in adults aged 50-59 years at increased risk of severe RSV disease (received FDA approval June 7, 2024)
- Continued discussion of safety, including risk of GBS, following RSV vaccination
- Shift from a shared clinical decision-making recommendation to:
  - Potential universal recommendation in adults 75 and older
  - Potential risk-based recommendation in adults 60–74
  - Potential risk-based recommendation in adults 50–59

Re-evaluating Shared Clinical Decision-Making (SCDM) recommendation

- In June 2023, ACIP recommended RSV vaccination in adults 60 and older using shared clinical decision-making
  - In addition to benefits of vaccination, the shared clinical decision-making discussion, as intended by ACIP, is also meant to include discussion of the potential risk of vaccine-associated adverse events associated with RSV vaccine, specifically Guillain Barre Syndrome.
- In the first year following this recommendation, we have learned:
  - Feedback from healthcare providers that having SCDM conversations is not simple in practice.
  - Unlike a universal recommendation where there's a clear call to action to vaccinate, with SCDM the call to action is to discuss with a healthcare provider, a less clear message.
- A risk-based recommendation for adults 60–74 and a universal recommendation for adults ≥75 years would potentially highlight more clearly for providers and other public health officials which adults are likely to benefit from an RSV vaccine and provide a clearer recommendation for patients.

Agenda: Wednesday June 26, 2024

Manufacturer presentation: ABRYSVO (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years	Dr. Iona Munjal (Pfizer)
Manufacturer presentation: AREXVY (GSK) immunogenicity with a 24-month revaccination interval	Dr. Susan Gerber (GSK)
Manufacturer presentation: mRESVIA (Moderna) season 2 safety and efficacy update	Dr. Rituparna Das (Moderna)
Postmarketing safety updates: Vaccine Safety Datalink	Dr. James Donahue (Marshfield Clinic Research Institute)
Evaluation of Guillain-Barre Syndrome (GBS) following RSV vaccination among adults 65 years and older	Dr. Patricia Lloyd (FDA)
Observational RSV vaccine effectiveness	Dr. Diya Surie (CDC, NCIRD)
Economic analysis of adult RSV vaccination	Dr. David Hutton (University of Michigan)
Update to benefits and risks discussion	Dr. David Hutton (University of Michigan)
Comparison of economic analyses of adult RSV vaccination	Dr. Ismael Ortega-Sanchez (CDC/NCIRD)
Evidence to Recommendations	Dr. Michael Melgar (CDC/NCIRD), Lauren Roper (CDC/NCIRD), Dr. Amadea Britton (CDC/NCIRD)
Clinical Considerations	Dr. Michael Melgar (CDC/NCIRD)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.